ProteomEdge
Stockholm, SE · 1 known investors
ProteomEdge develops mass spectrometry-based analytical platforms and proprietary heavy-labelled protein standard panels for absolute protein quantification in blood plasma, targeting clinically relevant biomarkers such as apolipoproteins, complement factors, and liver disease markers. Its products serve research and translational proteomics customers, including academic core facilities and precision medicine researchers. Based in Stockholm, Sweden.
Founders & leadership
MU
Mathias UhlénCo-founder & Chairman of the Board
HE
Henrik EverbergCEO
MH
Marianne HanssonFormer part-time CEO